Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Zalcman

Showing results (1-10 of 113) with videos related to

Pageof 12
Sort By:
Revue Des Maladies Respiratoires|August 12, 2003
[How to target biotherapies of lung cancer? Bronchoscopic biopsy and the immunohistochemical detection of the EGF-receptor]G Zalcman
Revue Des Maladies Respiratoires|October 11, 2007
[DNA Chips in thoracic oncology: molecular diagnosis and the definition of new therapeutic targets, a revolution in progress]E Bergot, G Zalcman
Revue De Pneumologie Clinique|July 23, 2011
[What is the best sequence of treatment for patients with EGFR mutations?]B Besse, G Zalcman
Revue Des Maladies Respiratoires|December 11, 2002
[New biological markers of lung cancer: toward targeted biotherapies?]G Zalcman, T Urban
Revue Des Maladies Respiratoires|May 2, 2008
[Research training in Pneumology, scholarships 2007]G Zalcman, J-C Meurice
Revue Des Maladies Respiratoires|June 22, 2006
[Scholarships in respiratory medicine, 2005]G Zalcman, J-C Meurice,
Revue Des Maladies Respiratoires|November 28, 2006
[Adjuvant chemotherapy for stage IB non small cell lung cancer: the standard of care?]P C Carré, G Zalcman
Revue Des Maladies Respiratoires|April 10, 2007
[Research training in respiratory medicine, 2006]G Zalcman, J C Meurice
The European Respiratory Journal|October 30, 2010
Genetic profiling and epidermal growth factor receptor-directed therapy in nonsmall cell lung cancerJ Cadranel, G Zalcman, L Sequist
Lung Cancer (Amsterdam, Netherlands)|February 1, 2011
Pemetrexed re-challenge in pleural malignant mesothelioma: an option for a subset of patients initially treated with pemetrexed-platinum doublets in the first-line setting?G Zalcman, E Bergot, E Lechapt
Pageof 12

Showing results (1-10 of 113) with videos related to

Sort By:
Pageof 12
Revue Des Maladies Respiratoires|August 12, 2003
[How to target biotherapies of lung cancer? Bronchoscopic biopsy and the immunohistochemical detection of the EGF-receptor]G Zalcman
Revue Des Maladies Respiratoires|October 11, 2007
[DNA Chips in thoracic oncology: molecular diagnosis and the definition of new therapeutic targets, a revolution in progress]E Bergot, G Zalcman
Revue De Pneumologie Clinique|July 23, 2011
[What is the best sequence of treatment for patients with EGFR mutations?]B Besse, G Zalcman
Revue Des Maladies Respiratoires|December 11, 2002
[New biological markers of lung cancer: toward targeted biotherapies?]G Zalcman, T Urban
Revue Des Maladies Respiratoires|May 2, 2008
[Research training in Pneumology, scholarships 2007]G Zalcman, J-C Meurice
Revue Des Maladies Respiratoires|June 22, 2006
[Scholarships in respiratory medicine, 2005]G Zalcman, J-C Meurice,
Revue Des Maladies Respiratoires|November 28, 2006
[Adjuvant chemotherapy for stage IB non small cell lung cancer: the standard of care?]P C Carré, G Zalcman
Revue Des Maladies Respiratoires|April 10, 2007
[Research training in respiratory medicine, 2006]G Zalcman, J C Meurice
The European Respiratory Journal|October 30, 2010
Genetic profiling and epidermal growth factor receptor-directed therapy in nonsmall cell lung cancerJ Cadranel, G Zalcman, L Sequist
Lung Cancer (Amsterdam, Netherlands)|February 1, 2011
Pemetrexed re-challenge in pleural malignant mesothelioma: an option for a subset of patients initially treated with pemetrexed-platinum doublets in the first-line setting?G Zalcman, E Bergot, E Lechapt
Pageof 12